Amneal Pharmaceuticals, Inc. Fundamental Analysis
Amneal Pharmaceuticals, Inc. Fundamental Analysis
Amneal Pharmaceuticals, Inc. (AMRX) shows weak financial fundamentals with a PE ratio of 45.61, profit margin of 4.02%, and ROE of -1.45%. The company generates $3.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 603.8/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze AMRX's fundamental strength across five key dimensions:
Efficiency Score
WeakAMRX struggles to generate sufficient returns from assets.
Valuation Score
ModerateAMRX shows balanced valuation metrics.
Growth Score
ModerateAMRX shows steady but slowing expansion.
Financial Health Score
ExcellentAMRX maintains a strong and stable balance sheet.
Profitability Score
WeakAMRX struggles to sustain strong margins.
Key Financial Metrics
Is AMRX Expensive or Cheap?
P/E Ratio
AMRX trades at 45.61 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, AMRX's PEG of 0.01 indicates potential undervaluation.
Price to Book
The market values Amneal Pharmaceuticals, Inc. at -125.17 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.81 times EBITDA. This is generally considered low.
How Well Does AMRX Make Money?
Net Profit Margin
For every $100 in sales, Amneal Pharmaceuticals, Inc. keeps $4.02 as profit after all expenses.
Operating Margin
Core operations generate 11.80 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.45 in profit for every $100 of shareholder equity.
ROA
Amneal Pharmaceuticals, Inc. generates $3.46 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Amneal Pharmaceuticals, Inc. generates limited operating cash flow of $294.70M, signaling weaker underlying cash strength.
Free Cash Flow
Amneal Pharmaceuticals, Inc. produces free cash flow of $199.09M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.62 in free cash annually.
FCF Yield
AMRX converts 3.72% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
45.61
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.005
vs 25 benchmark
P/B Ratio
Price to book value ratio
-125.17
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.81
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-59.38
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.47
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-1.45
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How AMRX Stacks Against Its Sector Peers
| Metric | AMRX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 45.61 | 29.63 | Worse (Expensive) |
| ROE | -144.72% | 223.00% | Weak |
| Net Margin | 4.02% | -38669.00% (disorted) | Weak |
| Debt/Equity | -59.38 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 2.47 | 4.30 | Strong Liquidity |
| ROA | 3.46% | -379.00% (disorted) | Weak |
AMRX outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Amneal Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation